CGC Webinars and Special Seminars
The Cancer Genomics Consortium is committed to providing high quality educational opportunities for members of the clinical genomics community. The CGC Webinar Series focuses on topics of high interest for CGC members, including implementation of new technologies in clinical genetic/genomic testing, standards and resources for interpretation of variants, germline predisposition to cancer, and novel approaches for detection of variants in constitutional and cancer samples. The CGC is also proud to offer Early Career webinars focused on subjects of interest to individuals in training or an early stage of their careers. Additionally, the CGC will continue the Genomics Case Conference Series, in collaboration with UW Collaborative Genomics Conference, in 2025. This lecture series provides a format for showcasing interesting and educational cases and consulting with colleagues about challenging test results.
The CGC Webinar Series is part of the CGC's commitment to providing high quality education that serves to enhance and expand the knowledge of clinical cancer genomics professionals for the better utilization of genomic technologies for clinical laboratory testing.
CGC Early Career Webinars are an initiative of the CGC Early Career Committee designed to meet the career and technical skill development needs of those in training or recently out of training.
This monthly series, sponsored by the CGC and the University of Wisconsin Collaborative Genomics Conference, offers staff and trainees an opportunity to present interesting cases to an international audience.
ISCN 2024 Update Webinar Series: Part 1 - Summary of changes introduced in ISCN 2024
Tuesday, April 15, 2025
9:00 AM PDT / 12:00 PM EDT
The International System for Cytogenomic Nomenclature (ISCN) enables individuals to describe and communicate effectively normal and abnormal results found in their research or diagnostic studies. The latest version of ISCN (ISCN 2024) represents one of the most significant reviews with the generic rules being codified, plus the inclusion of genome mapping, targeted karyotyping, targeted arrays, imprinted and fusion gene nomenclature. ISCN 2024 provides a more user friendly and organized presentation of general rules, and improved example descriptions. There are additional worked examples for mixed cell populations, complete moles, composite karyotypes, uniparental disomy and more complex results. A key achievement is the provision of standardized nomenclature to ensure consistency in the ISCN description of findings irrespective of the technology used.
This webinar is suitable for all staff working in genomics, especially those working in the field of cytogenomics. Ros Hastings, Ph.D., Chair of the ISCN Standing Committee will present on the changes to ISCN 2024 including their application in a diagnostic setting. Participants will gain an understanding of the new nomenclature in different settings through the worked examples during this webinar. The interactive quiz session will enable participants to see how much they have understood and where further education is required.
Level of Instruction: Intermediate to Advanced
Learning Objectives: At the end of this session, participants will be able to:
- Understand the rules and the practical application of cytogenomic ISCN nomenclature
- Differentiate when to apply ISCN or HGVS nomenclature
- Formulate and use the ISCN 2024 nomenclature in their own laboratories, clinical practices and in publications.
- Apply ISCN for real complex examples.
Ros Hastings PhD, FRCpath
GenQA Consultant for Cytogenomics, Oxford and Edinburgh, UK
Chair of the ISCN Standing Committee
Dr. Hastings is a state registered clinical scientist and a Fellow of the Royal College of Pathologists. She has more than 35 years’ experience in constitutional (including prenatal), acquired and molecular cytogenomics, both in a research and diagnostic setting in the UK. Initially, Dr Hastings worked on research projects into cancer and immunological disorders at the Imperial Cancer Research Fund, London; the MRC Cytogenetics Unit, Edinburgh and the Cancer Research Campaign Laboratory, Manchester. She has also worked in four diagnostic Cytogenetics Laboratories within the UK. For past 20 years she was the Director of an ISO accredited proficiency testing (PT) provider for cytogenomics and more latterly, genomics (CEQAS and GenQA). Dr Hastings now works part time, as a Cytogenomics Consultant for GenQA, an ISO accredited PT provider operated by Oxford University Hospitals NHS Foundation Trust, Oxford. Dr Hastings is the Chair of the ISCN Standards Committee (since 2020), editor of ISCN 2020 and lead editor of ISCN 2024.
Dr Hastings has authored many publications and book chapters on genetics, NIPT, PGD, ISCN and PT. In addition, she is an author on many best practice guidelines.
ISO - International Standards Organisation
GenQA - Genomics External Quality Assessment
PT- Proficiency testing
ISCN 2024 Update Webinar Series: Part 2 - Neoplasia specific ISCN including order of clones and composite karyotypes examples
Tuesday, April 22, 2025
9:00 AM PDT / 12:00 PM EDT
The International System for Cytogenomic Nomenclature (ISCN) enables individuals to describe and communicate effectively normal and abnormal results found in their research or diagnostic studies. The latest version of ISCN (ISCN 2024) represents one of the most significant reviews with the generic rules being codified, plus the inclusion of genome mapping, targeted karyotyping, targeted arrays, imprinted and fusion gene nomenclature. ISCN 2024 provides a more user friendly and organized presentation of general rules, and improved example descriptions. There are additional worked examples for mixed cell populations, complete moles, composite karyotypes, uniparental disomy and more complex results. A key achievement is the provision of standardized nomenclature to ensure consistency in the ISCN description of findings irrespective of the technology used.
This webinar is suitable for all staff working in genomics, especially those working in the field of cytogenomics. Ros Hastings, Ph.D., Chair of the ISCN Standing Committee will present on the changes to ISCN 2024 including their application in a diagnostic setting. Participants will gain an understanding of the new nomenclature in different settings through the worked examples during this webinar. The interactive quiz session will enable participants to see how much they have understood and where further education is required.
Level of Instruction: Intermediate to Advanced
Learning Objectives: At the end of this session, participants will be able to:
- Understand the rules and the practical application of cytogenomic ISCN nomenclature
- Differentiate when to apply ISCN or HGVS nomenclature
- Formulate and use the ISCN 2024 nomenclature in their own laboratories, clinical practices and in publications.
- Apply ISCN for real complex examples.
Ros Hastings PhD, FRCpath
GenQA Consultant for Cytogenomics, Oxford and Edinburgh, UK
Chair of the ISCN Standing Committee
Dr. Hastings is a state registered clinical scientist and a Fellow of the Royal College of Pathologists. She has more than 35 years’ experience in constitutional (including prenatal), acquired and molecular cytogenomics, both in a research and diagnostic setting in the UK. Initially, Dr Hastings worked on research projects into cancer and immunological disorders at the Imperial Cancer Research Fund, London; the MRC Cytogenetics Unit, Edinburgh and the Cancer Research Campaign Laboratory, Manchester. She has also worked in four diagnostic Cytogenetics Laboratories within the UK. For past 20 years she was the Director of an ISO accredited proficiency testing (PT) provider for cytogenomics and more latterly, genomics (CEQAS and GenQA). Dr Hastings now works part time, as a Cytogenomics Consultant for GenQA, an ISO accredited PT provider operated by Oxford University Hospitals NHS Foundation Trust, Oxford. Dr Hastings is the Chair of the ISCN Standards Committee (since 2020), editor of ISCN 2020 and lead editor of ISCN 2024.
Dr Hastings has authored many publications and book chapters on genetics, NIPT, PGD, ISCN and PT. In addition, she is an author on many best practice guidelines.
ISO - International Standards Organisation
GenQA - Genomics External Quality Assessment
PT- Proficiency testing
ISCN 2024 Update Webinar Series: Part 3 - Optical genome mapping nomenclature
Tuesday, May 20, 2025
9:00 AM PDT / 12:00 PM EDT
The International System for Cytogenomic Nomenclature (ISCN) enables individuals to describe and communicate effectively normal and abnormal results found in their research or diagnostic studies. The latest version of ISCN (ISCN 2024) represents one of the most significant reviews with the generic rules being codified, plus the inclusion of genome mapping, targeted karyotyping, targeted arrays, imprinted and fusion gene nomenclature. ISCN 2024 provides a more user friendly and organized presentation of general rules, and improved example descriptions. There are additional worked examples for mixed cell populations, complete moles, composite karyotypes, uniparental disomy and more complex results. A key achievement is the provision of standardized nomenclature to ensure consistency in the ISCN description of findings irrespective of the technology used.
This webinar is suitable for all staff working in genomics, especially those working in the field of cytogenomics. Ros Hastings, Ph.D., Chair of the ISCN Standing Committee will present on the changes to ISCN 2024 including their application in a diagnostic setting. Professor Jean McGowan-Jordan, Ph.D., will join Dr. Hastings to present worked examples using the nomenclature. Participants will gain an understanding of the new nomenclature in different settings through the worked examples during this webinar. The interactive quiz session will enable participants to see how much they have understood and where further education is required.
Level of Instruction: Intermediate to Advanced
Learning Objectives: At the end of this session, participants will be able to:
- Understand the rules and the practical application of cytogenomic ISCN nomenclature
- Differentiate when to apply ISCN or HGVS nomenclature
- Formulate and use the ISCN 2024 nomenclature in their own laboratories, clinical practices and in publications.
- Apply ISCN for real complex examples.
Ros Hastings PhD, FRCpath
GenQA Consultant for Cytogenomics, Oxford and Edinburgh, UK
Chair of the ISCN Standing Committee
Dr. Hastings is a state registered clinical scientist and a Fellow of the Royal College of Pathologists. She has more than 35 years’ experience in constitutional (including prenatal), acquired and molecular cytogenomics, both in a research and diagnostic setting in the UK. Initially, Dr Hastings worked on research projects into cancer and immunological disorders at the Imperial Cancer Research Fund, London; the MRC Cytogenetics Unit, Edinburgh and the Cancer Research Campaign Laboratory, Manchester. She has also worked in four diagnostic Cytogenetics Laboratories within the UK. For past 20 years she was the Director of an ISO accredited proficiency testing (PT) provider for cytogenomics and more latterly, genomics (CEQAS and GenQA). Dr Hastings now works part time, as a Cytogenomics Consultant for GenQA, an ISO accredited PT provider operated by Oxford University Hospitals NHS Foundation Trust, Oxford. Dr Hastings is the Chair of the ISCN Standards Committee (since 2020), editor of ISCN 2020 and lead editor of ISCN 2024.
Dr Hastings has authored many publications and book chapters on genetics, NIPT, PGD, ISCN and PT. In addition, she is an author on many best practice guidelines.
ISO - International Standards Organisation
GenQA - Genomics External Quality Assessment
PT- Proficiency testing
Jean McGowan-Jordan, PhD, FCCMG
Clinical Cytogeneticist, Children’s Hospital of Eastern Ontario (CHEO)
Professor, Department of Pathology and Laboratory Medicine, University of Ottawa, Canada
Dr. Jean McGowan-Jordan has led the CHEO Genetics Diagnostic Lab (GDL), which is an integrated regional lab with both Cytogenomic and Molecular Genetics sections. She is a Professor in the Department of Pathology and Laboratory Medicine at the University of Ottawa. After completing fellowships in Molecular Genetics and Cytogenetics in Ottawa and Kingston, she was credentialed in both specialties through the Canadian College of Medical Geneticists (CCMG). She was instrumental in the early transition of prenatal diagnosis of aneuploidies in Eastern Ontario to a more efficient molecular-based approach and was heavily involved in the introduction of SNP microarray testing in her lab. Her lab has introduced a stand-alone clinical test for Facioscapulohumeral Muscular Dystrophy using Optical Genome Mapping, and is implementing this exciting technology for analysis of acute leukemias and myeloid disorders.
Dr. McGowan-Jordan has served on the CCMG Board of Directors, the CCMG Genetics and Genome Diagnostics Working Group, and Cytogenetics Committee. Internationally, Dr. McGowan-Jordan was Chair of the Standing Committee for the International System for Human Cytogenomic Nomenclature (ISCN) from 2013 to 2020, serving as lead editor of ISCN 2016 and ISCN 2020. She is currently an Advisor to this group and coauthored the new nomenclature for Genome Mapping in the ISCN 2024.
Coffee Break with CGC Mentors
Multiple sessions available beginning Tuesday, April 29, 2025
Various Times Available
- Are you a trainee or early career (1-3 years after training) CGC member?
- Would you like to broaden your perspective by making professional contacts at different institutions?
- Do you have questions relevant to your training or career development?
- Would it be helpful to meet with an expert member in your field to answer these questions and more?
Then you are invited to join us for the Spring 2025 Coffee Break with CGC Mentors!
These mentoring sessions, lasting one hour and facilitated by a CGC mentor, have a limit of six trainee/early career CGC members per session. Sign ups are on a first-come basis and are limited to foster effective small group engagement.
This event is open to current CGC members only. If you aren’t a CGC member, you can become a member today!
For more information about Coffee Breaks with CGC Mentors and the Spring 2025 mentors, please CLICK HERE.
Catherine Cottrell
Nationwide Children's Hospital
Jennifer Laffin
University of Minnesota, Twin Cities
Jerry Machado
Exact Sciences
Swaroop Aradhya
Illumina
Xiaoming "Mindy" Wang
University of Michigan
Ngoni Faya
Cincinnati Children's Hospital
Sarah South
Quest Diagnostics
Alex Wagner
Nationwide Children's Hospital
To learn more about the mentors and potential discussion topics, please the Coffee Break with CGC Mentors webpage.
Early Career Virtual Social
Tuesday, April 8, 2025
12:00 PM PDT / 3:00 PM EDT
Please join us for a virtual event hosted by the CGC Early Career Initiative Committee to learn more about the benefits of CGC membership and to connect with others at similar career stages. We will provide an overview of current and upcoming CGC programs that benefit and support trainees and other individuals early in their careers or new to the CGC.
Representatives from the CGC Board of Directors, Membership Committee, Early Career Committee, Genomic Resources Development Committee, and Annual Meeting Program Committee will also be present as speakers and to answer questions about the array of CGC programs. During the second half of the meeting, attendees will have the opportunity to join Zoom break out rooms for informal networking with peers and representatives from the CGC.
This event is open to both CGC members and non-members.
Jane Houldsworth
CGC President
Joie Olayiwola
Co-lead of the Geneticist Toolkit project, a free educational resource available for CGC members
Alex Wagner
Chair of the CGC Membership Committee
Jeanine Ruggeri
Representative from the Early Career Committee
Building on the remarkable success of this educational series, the CGC Education committee is excited to continue the monthly case conference series offered in collaboration with the UW Collaborative Genomics Conference in 2025.
This lecture series focuses on topics of high interest for CGC members and attendees of the UW Collaborative Genomic Conference, including implementation of new technologies in clinical genetic/genomic testing, standards and resources for interpretation of sequence and copy number variants, germline predisposition to cancer, and novel approaches for detection of structural variants in constitutional and cancer samples. The CGC is currently accepting cases for inclusion in the 2025 Case Conference Series.
These conferences will allow CGC members to: showcase their interesting and educational cases, promote their clinical and research work, consult with colleagues about challenging test results, earn CE credits at no charge through the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP), and identify collaborators with similar cases and shared clinical or research interests. Additional benefits for trainees include winning the 'Best Case Presentation' award and the option to submit a case report for publication in the Cancer Genetics journal.
2025 Collaborative Genomics Case Conference Series Webinars
Tuesday, April 22, 2025
1:00 PM CST/ 2:00 PM EST
Unraveling Mosaic Aneuploidy: Two Prenatal Case Studies in Placental and Amniotic Fluid Discrepancies*
Xinming Zhuo, PhD
* CME credit will not be offered for this session.
Tuesday, May 13, 2025
1:00 PM CST/ 2:00 PM EST
Speakers for the May 2025 Case Conference webinar will be announced soon.
Tuesday, June 24, 2025
1:00 PM CST/ 2:00 PM EST
Speakers for the June 2025 Case Conference webinar will be announced soon.
To attend, click the button below
to join the conference:
Meeting ID: 945 6708 1449
Passcode: CGC2024-26
- Register for an account with the University of Wisconsin Interprofessional Continuing Education Partnership (UW-ICEP)
- Per new ACCME’s Standards-UW Madison, ALL attendees must text the code every time to confirm attendance, (deadline to text the code is 48 hours after the end of the conference). Instructions for texting your attendance will be provided at the event.
- Complete the online evaluation (must be completed within 45 days after the conference).
- You can track your participation through your account with ICEP.
